EI- Nile for Pharmaceuticals and Chemical Industries Valuation

Is NIPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NIPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NIPH (EGP55.22) is trading below our estimate of fair value (EGP296.75)

Significantly Below Fair Value: NIPH is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NIPH?

Key metric: As NIPH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NIPH. This is calculated by dividing NIPH's market cap by their current earnings.
What is NIPH's PE Ratio?
PE Ratio	22.7x
Earnings	ج.م24.65m
Market Cap	ج.م559.10m

NIPH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.2x
Enterprise Value/EBITDA	6.7x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does NIPH's PE Ratio compare to its peers?

The above table shows the PE ratio for NIPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	5.3x
ADCI Arab Drug	6.4x	n/a	ج.م619.3m
MPCI Memphis Pharmaceuticals & Chemical Industries	1.1x	n/a	ج.م324.1m
OCPH October PharmaE	7x	n/a	ج.م1.3b
AXPH Alexandria For Pharmaceuticals & Chemical Industries	6.7x	n/a	ج.م1.5b
NIPH EI- Nile for Pharmaceuticals and Chemical Industries	22.7x	n/a	ج.م559.1m

Price-To-Earnings vs Peers: NIPH is expensive based on its Price-To-Earnings Ratio (22.7x) compared to the peer average (5.3x).

Price to Earnings Ratio vs Industry

How does NIPH's PE Ratio compare vs other companies in the African Pharmaceuticals Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: NIPH is expensive based on its Price-To-Earnings Ratio (22.7x) compared to the African Pharmaceuticals industry average (11.6x).

Price to Earnings Ratio vs Fair Ratio

What is NIPH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NIPH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	22.7x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NIPH's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.